IPSEN |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.4 EUR | -1.57% |
|
-1.89% | +10.66% |
| May. 28 | Ipsen S.A. Approves Dividend, Payable on 3 June 2024 | CI |
| May. 14 | Ipsen: share price up, analyst raises target | CF |
| Sales 2024 * | 3.47B 3.76B | Sales 2025 * | 3.71B 4.02B | Capitalization | 9.86B 10.71B |
|---|---|---|---|---|---|
| Net income 2024 * | 648M 704M | Net income 2025 * | 721M 783M | EV / Sales 2024 * | 2.69 x |
| Net cash position 2024 * | 545M 591M | Net cash position 2025 * | 1.19B 1.29B | EV / Sales 2025 * | 2.34 x |
| P/E ratio 2024 * |
15.6
x | P/E ratio 2025 * |
14
x | Employees | 5,325 |
| Yield 2024 * |
1.01% | Yield 2025 * |
1% | Free-Float | 41.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen
More press releases
More news
| 1 day | -1.57% | ||
| 1 week | -1.89% | ||
| Current month | +4.65% | ||
| 1 month | +5.66% | ||
| 3 months | +15.36% | ||
| 6 months | +15.81% | ||
| Current year | +10.66% |
1 week
119.30
124.50
1 month
111.30124.50
Current year
99.70124.50
1 year
99.70130.70
3 years
77.00130.70
5 years
34.20130.70
10 years
31.50155.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 55 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Chairman | 66 | 10-11-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 2 M€ | +11.90% | ||
| 0.43% | 242 M€ | +10.60% | ||
| 0.31% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 119.4 | -1.57% | 85,313 |
| 24-05-27 | 121.3 | -1.70% | 50,046 |
| 24-05-24 | 123.4 | -0.16% | 74,948 |
| 24-05-23 | 123.6 | +1.15% | 81,203 |
| 24-05-22 | 122.2 | +0.74% | 78,745 |
Real-time Euronext Paris, May 28, 2024 at 11:35 am EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-29
- Ex-dividend day for final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
119.4
EUR
Average target price
126.4
EUR
Spread / Average Target
+5.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.66% | 10.88B | |
| +38.59% | 727B | |
| -7.89% | 354B | |
| +15.66% | 328B | |
| +0.24% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.23% | 164B | |
| -1.70% | 164B |
- Stock Market
- Equities
- IPN Stock
